Novo Nordisk Ltd. (pharmaceutical industry)
AuthorMatin, Md. Zubair
MetadataShow full item record
Bangladesh is a densely populated country situated at South- East Asia. Although the geographical area of the country is not that big, but the country is huge (8th in the world) in terms of the population (close to 160 million). Considering diabetes under the health sector, 5.9 million people have diabetes today and that would rise to 16.6 million by 2030. Per capita health expenditure is 152 DKK which is 3.7% of the GDP. To combat the disease, groups and institutions are serving through different public and private hospitals. Besides, Diabetes Association of Bangladesh (BADAS) is playing a crucial role. Everyday more than 12,000 patients are served by them through different DAB centres, National Health Care Network (NHN) centres, Health Care Development Project (HCDP) centres around the country. This altogether constitutes a complete and integrated diabetes care management system in the country. Having this world class diabetes care infrastructure in place, only 25% patients have access to treatment and within that 25% also the treatment outcome needs further improvement. There is an urgent need for change, which can be brought in through the Changing Diabetes® Barometer (CDB) and Novo Care Project.